Cencora, Inc. (NYSE:COR) Shares Bought by V Square Quantitative Management LLC

V Square Quantitative Management LLC raised its stake in Cencora, Inc. (NYSE:COR) by 2.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,725 shares of the company’s stock after acquiring an additional 91 shares during the quarter. V Square Quantitative Management LLC’s holdings in Cencora were worth $837,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. Swedbank AB grew its position in shares of Cencora by 2.3% in the third quarter. Swedbank AB now owns 1,394,449 shares of the company’s stock valued at $313,863,000 after purchasing an additional 31,104 shares during the period. Vontobel Holding Ltd. grew its position in Cencora by 1.4% during the third quarter. Vontobel Holding Ltd. now owns 4,250 shares of the company’s stock valued at $957,000 after acquiring an additional 58 shares during the period. Good Life Advisors LLC grew its position in Cencora by 81.7% during the third quarter. Good Life Advisors LLC now owns 3,050 shares of the company’s stock valued at $687,000 after acquiring an additional 1,371 shares during the period. Vista Investment Partners LLC grew its position in Cencora by 0.5% during the third quarter. Vista Investment Partners LLC now owns 19,483 shares of the company’s stock valued at $4,385,000 after acquiring an additional 90 shares during the period. Finally, Sumitomo Mitsui DS Asset Management Company Ltd grew its position in Cencora by 1.1% during the third quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 28,285 shares of the company’s stock valued at $6,366,000 after acquiring an additional 305 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Evercore ISI boosted their price target on Cencora from $270.00 to $280.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. JPMorgan Chase & Co. boosted their price target on Cencora from $289.00 to $301.00 and gave the company an “overweight” rating in a research report on Friday, January 24th. Barclays upped their target price on Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Robert W. Baird upped their target price on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Finally, Wells Fargo & Company upped their target price on Cencora from $237.00 to $251.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 29th. Two investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $277.90.

Insider Buying and Selling at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the sale, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the sale, the chairman now owns 306,752 shares in the company, valued at $74,283,064.32. The trade was a 6.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 73,187 shares of company stock worth $17,790,912 over the last quarter. 10.80% of the stock is owned by corporate insiders.

Cencora Trading Down 0.6 %

NYSE:COR opened at $243.03 on Friday. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.53 and a current ratio of 0.92. Cencora, Inc. has a one year low of $214.77 and a one year high of $262.26. The business’s 50-day simple moving average is $238.70 and its 200 day simple moving average is $237.38. The stock has a market cap of $46.97 billion, a price-to-earnings ratio of 34.57, a price-to-earnings-growth ratio of 1.49 and a beta of 0.49.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. As a group, sell-side analysts predict that Cencora, Inc. will post 15.36 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Shareholders of record on Friday, February 14th will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.91%. The ex-dividend date is Friday, February 14th. Cencora’s payout ratio is currently 31.29%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.